A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
Status:
Completed
Trial end date:
2019-12-10
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability of perampanel
administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12
milligrams per day [mg/day]) as an adjunctive therapy in participants with epilepsy with
partial onset seizures (POS) (including secondarily generalized seizures) or primary
generalized tonic-clonic (PGTC) seizures.